Mark M Sieczkarek Net Worth

The estimated Net Worth of Mark M Sieczkarek is at least 94.2 千$ dollars as of 3 March 2015. Mark Sieczkarek owns over 166,666 units of Novabay Pharmaceuticals Inc stock worth over 94,166$ and over the last 11 years Mark sold NBY stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Sieczkarek NBY stock SEC Form 4 insiders trading

Mark has made over 3 trades of the Novabay Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Mark bought 166,666 units of NBY stock worth 100,000$ on 3 March 2015.

The largest trade Mark's ever made was buying 166,666 units of Novabay Pharmaceuticals Inc stock on 3 March 2015 worth over 100,000$. On average, Mark trades about 9,356 units every 14 days since 2014. As of 3 March 2015 Mark still owns at least 196,466 units of Novabay Pharmaceuticals Inc stock.

You can see the complete history of Mark Sieczkarek stock trades at the bottom of the page.

What's Mark Sieczkarek's mailing address?

Mark's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608.

Insiders trading at Novabay Pharmaceuticals Inc

Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over 3,799,939$ worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth 26,237,091$ . The most active insiders traders include Pharma (Singapore) Pte. Ltd...、Pioneer Pharma Holdings Ltd...、Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of 127,779$. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth 411$.

What does Novabay Pharmaceuticals Inc do?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Complete history of Mark Sieczkarek stock trades at Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc executives and stock owners

Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Justin M. Hall Esq.,
  Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director
• Justin Hall,
  President, Chief Executive Officer, Director
• Andrew Jones,
  Chief Financial Officer, Treasurer
• Swan Sit,
  Independent Director
• Yenyou Zheng,
  Independent Director
• Paul Freiman,
  Independent Director
• Mijia Wu,
  Director
• Xinzhou Li,
  Director
• Dr. Jeffrey Kunin M.D.,
  Pres of DERMAdoctor
• Dr. Audrey Kunin M.D.,
  Chief Product Officer
• Yongxiang Zheng,
  Director
• Julie Garlikov,
  Director
• Wang Xu,
  NEO - Sr Mgr and Controller
• Lewis J Stuart,
  Chief Commercial Officer
• Yanbin Liu,
  Director
• Jason Philip Raleigh,
  Interim CFO and Treasurer
• Xiaoyan Liu,
  Director
• Gail J Maderis,
  Director
• Todd Erik Zavodnick,
  Director
• Pharma (Singapore) Pte. Ltd...,
  10% owner
• T. Alex Mc Pherson,
  Director
• Thomas J Paulson,
  Chief Financial Officer
• Yonghao Ma,
  Director
• Jian Ping Fu,
  10% owner
• Massimo Radaelli,
  Director
• Mark M Sieczkarek,
  Director
• Pharma (Hong Kong) Co Ltd P...,
  10% owner
• John Joseph Mc Govern,
  Int Pres, CEO, CFO & Treasurer
• John James O'reilly,
  Chief Financial Officer
• Colin Scott,
  VP, Clinical Research & Dev't
• Keith R Bley,
  SVP Product Development
• Pioneer Pharma Holdings Ltd...,
  10% owner
• Roy J Wu,
  SVP Bus & Corp Development
• David W. Stroman,
  SVP, Ophthalmic Product Devt.
• Tony D.S. Wicks,
  Director
• Anthony Dailley,
  Director
• Robert R. Tufts,
  Director
• Charles Cashion,
  Director
• Behzad Khosrovi,
  VP, Research & Dev't
• Ramin Najafi,
  Chief Executive Officer
• Area Pioneer Pharma Co., Lt...,
  10% owner
• Ramin Najafi Family Trust D...,
  Chief Executive Officer
• Mark Brian Anderson,
  CSO
• Harry F Jr Hixson,
  Director
• Russell A. Hoon,
  Senior Vice President
• Xiaopei Wang,
  
• Jeffrey Kunin,
  President, DERMAdoctor, LLC
• Audrey Kunin,
  Chief Product Officer